Effect of Chinese medicine for promoting blood circulation on microvascular angina: A systematic review and meta-analysis
- PMID: 33046314
- DOI: 10.1016/j.ajem.2020.07.072
Effect of Chinese medicine for promoting blood circulation on microvascular angina: A systematic review and meta-analysis
Abstract
Background: Blood-activating drugs (BADs) are widely used to treat microvascular angina in China. This study aims to summarize relevant evidence from randomized controlled trials (RCTs) to assess the efficacy and safety of BADs in the treatment of microvascular angina.
Methods: We searched for relevant studies before June 2019 from seven databases. Twenty-four studies were included of 1903 patients with microvascular angina. All studies compared the use of traditional Chinese medicine for activating blood circulation (BADs) and Western medicine (WM) with the use of Western medicine alone.
Results: In all, 15 trials reported a significant effect of BADs on improving clinical symptoms compared with the control treatment (P < .00001), and 8 trials reported significant effects of BADs on reducing the frequency of angina pectoris attacks compared with Western medicine treatment (P < .00001). The pooled results also demonstrated that BADs provided a significant benefit in reducing the dosage of nitroglycerin required (P = .02), the maximum range of ST-segment depression (P = .003) and the descending degree of the ST-T segment of ECG (P = .0002); prolonging the total time of treadmill exercise (P < .00001) and the time of ST-segment depression of 1 mm (P = .002); enhancing the total effective rate of Traditional Chinese Medicine (TCM) syndromes (P < .00001); improving endothelial function (P < .00001); and reducing the levels of high-sensitivity C-reactive protein (hs-CRP) (P < .00001). BAD treatment showed no statistically significant effect on the levels of TNF-a (P = .8) or IL-6 (P = .13). No severe adverse events were reported.
Conclusion: This meta-analysis shows that BADs are effective for the treatment of microvascular angina. Although concerns regarding selective bias and low methodological quality were raised, our findings suggest that BADs are beneficial for patients with microvascular angina and should be given priority for future clinical studies.
Keywords: A systematic review and meta-analysis; Blood-activating drug; Microvascular angina.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare no conflicts of interest.
Similar articles
-
The effect of nicorandil in patients with cardiac syndrome X: A meta-analysis of randomized controlled trials.Medicine (Baltimore). 2020 Sep 11;99(37):e22167. doi: 10.1097/MD.0000000000022167. Medicine (Baltimore). 2020. PMID: 32925783 Free PMC article.
-
[Shensong Yangxin Capsules in the adjuvant treatment of stable angina pectoris:a Meta-analysis and trial sequential analysis].Zhongguo Zhong Yao Za Zhi. 2019 Sep;44(17):3816-3824. doi: 10.19540/j.cnki.cjcmm.20190624.503. Zhongguo Zhong Yao Za Zhi. 2019. PMID: 31602958 Chinese.
-
Traditional Chinese medicine for stable angina pectoris via TCM pattern differentiation and TCM mechanism: study protocol of a randomized controlled trial.Trials. 2014 Oct 30;15:422. doi: 10.1186/1745-6215-15-422. Trials. 2014. PMID: 25359307 Free PMC article. Clinical Trial.
-
[Outcome indicators in clinical trials on traditional Chinese medicine treatment of microvascular angina].Zhongguo Zhong Yao Za Zhi. 2023 Aug;48(16):4508-4520. doi: 10.19540/j.cnki.cjcmm.20230509.501. Zhongguo Zhong Yao Za Zhi. 2023. PMID: 37802877 Clinical Trial. Chinese.
-
A systematic review and meta-analysis of clinical research on treating angina pectoris of coronary heart disease with traditional Chinese medicine to promote blood circulation and remove blood stasis.Ann Palliat Med. 2021 Oct;10(10):10506-10514. doi: 10.21037/apm-21-2233. Ann Palliat Med. 2021. PMID: 34763497
Cited by
-
Generation of a medicine food homology formula and its likely mechanism in treatment of microvascular angina.Front Pharmacol. 2024 Aug 30;15:1404874. doi: 10.3389/fphar.2024.1404874. eCollection 2024. Front Pharmacol. 2024. PMID: 39281275 Free PMC article.
-
Traditional chinese medicine in coronary microvascular disease.Front Pharmacol. 2022 Aug 8;13:929159. doi: 10.3389/fphar.2022.929159. eCollection 2022. Front Pharmacol. 2022. PMID: 36003524 Free PMC article. Review.
-
Effects of Shexiang Baoxin Pill for Coronary Microvascular Function: A Systematic Review and Meta-Analysis.Front Pharmacol. 2021 Nov 2;12:751050. doi: 10.3389/fphar.2021.751050. eCollection 2021. Front Pharmacol. 2021. PMID: 34795585 Free PMC article. Review.
-
Combined Therapy with Traditional Chinese Medicine and Antiplatelet Drugs for Ischemic Heart Disease: Mechanism, Efficacy, and Safety.Evid Based Complement Alternat Med. 2021 Oct 27;2021:9956248. doi: 10.1155/2021/9956248. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34745309 Free PMC article. Review.
-
Efficacy and safety of Qi-Jing Hui-Xin Decoction in the treatment of coronary microvascular angina: study protocol for a randomized, controlled, multi-center clinical trial.Trials. 2021 Aug 21;22(1):553. doi: 10.1186/s13063-021-05508-x. Trials. 2021. PMID: 34419124 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous